Generic Growth Opportunities Are Significant, With an Estimated $100bn Worth of Branded Pharmaceutical Products to Go Off Patent By 2010, of Which $21bn Expire in 2006
Posted on: Thursday, 13 April 2006, 09:01 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c35683) has announced the addition of "The Top 10 Generics Companies: Strategic Insight, Growth Opportunities and Competitive Dynamics in the US and Europe" to their offering.
The generics sector has grown at a fast pace over the past few years, outperforming the pharmaceutical market as a whole; generic growth opportunities are significant, with an estimated $100bn worth of branded pharmaceutical products to go off patent by 2010, of which $21bn expire in 2006. Although US and major European generic drug sales increased rapidly from 2000 to 2003, there has been a slowdown in growth during 2004. In response to an increasingly competitive unbranded generic pharmaceutical marketplace, and a slowdown in growth in 2004, some of the major generics players have consolidated. The two largest M&A deals in the generics market in recent years have been the acquisition of Eon and HEXAL Labs by Sandoz in February 2005, and the acquisition of IVAX by Teva in January 2006.
"The Top 10 Generics Companies: Strategic Insight, Growth Opportunities and Competitive Dynamics in the US and Europe" identifies the successful strategies utilized by the industry's key players in the US and Western European market. The report provides insights into the top 10 generic companies strengths, weaknesses, opportunities and threats in the generic pharmaceutical market, allowing you to tailor the best practice strategies of the generic industry's leading players to your company's needs.
Key topics covered:
- The generics market in US and Europe - Teva/IVAX - Sandoz (incl. Eon Labs and HEXAL) - Mylan - Ratiopharm - Watson Pharmaceuticals Inc. - Par Pharmaceuticals, Inc. - Merck KGaA - Baxter International Inc. - STADA - Apotex
For more information visit http://www.researchandmarkets.com/reports/c35683
Source: Business Insights
Source: Business Wire
Related Articles
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
- Teva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in Japan
- Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson's Disease Drug Market Over the Next Decade
- 'Conservative' Pharmaceutical Industry Slow to Take Advantage of Online Marketing Opportunities
- Verispan Recognizes Sucampo Pharmaceuticals As a Top 20 Pharmaceutical Company in Promoting to the U.S. Nursing Home Market
- Attorney Shawn Khorrami Releases Commentary in Response to Government Inquiries Into Off-Label Drug Use Marketing By Pharmaceutical Companies
- Obesity Presents New Market Opportunities for Pharmaceutical Companies
- Spectrum Announces Strategic Alliance With Par Pharmaceutical Companies, Inc. For Sales and Distribution of Spectrum's Generic Product Line
- KV Pharmaceutical Company to Market New Generic Drugs in U.S. Via Exclusive Deal With Gedeon Richter
 |
 |
User Comments (0)
RSS Feeds